Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Navlimetostat · BMS-986504, MRTX1719

Small molecule · Inhibitor of PRMT5 · developed by BRISTOL MYERS SQUIBB

Phase 2/3 Most advanced trial
BMY Developer
3 Registered trials

What is Navlimetostat?

Navlimetostat is an orally bioavailable, methylthioadenosine (MTA)-selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It binds PRMT5 complexed with MTA, which is elevated in MTAP-deleted cancer cells, reducing histone arginine methylation, dysregulating RNA splicing and decreasing pRb, and is being studied in MTAP-deleted non-small cell lung cancer and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BMS-986504, MRTX1719
Drug type
Small molecule
Targets
PRMT5
Mechanism
Inhibitor of PRMT5
Pathways
histone arginine methylation, RNA splicing, retinoblastoma protein (pRb) regulation, apoptosis
Therapy area
Oncology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
UHN5PKM648

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07063745 Phase 2/3 Metastatic Non-small Cell Lung Cancer With MTAP Deletion Recruiting BMY
NCT07492680 Phase 2 Solid Tumors Recruiting BMY
NCT07777133 Phase 1 Healthy Female Participants Recruiting BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Female ParticipantsMetastatic Non-small Cell Lung Cancer With MTAP DeletionSolid Tumors

Other drugs acting on PRMT5

More from BRISTOL MYERS SQUIBB

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Navlimetostat

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.